Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MMP13 | P45452 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14966646 | 0.90 | KLKB1 (0.46) | MAPK14HPGDSMN1; SMN2LMNAMMP13 | |
| SCHEMBL14966820 | 0.89 | SMN1; SMN2 (0.47) | MAPK14HPGDSMN1; SMN2LMNAMMP13 | |
| SCHEMBL14966690 | 0.89 | MAPK14 (0.54) | MAPK14HPGDSMN1; SMN2LMNAMMP13 | |
| SCHEMBL14966964 | 0.88 | MAPK14 (0.53) | MAPK14HPGDSMN1; SMN2LMNAMMP13 | |
| SCHEMBL14966960 | 0.88 | SMN1; SMN2 (0.54) | MAPK14HPGDSMN1; SMN2LMNAMMP13 | |
| SCHEMBL14967238 | 0.87 | KLKB1 (0.44) | MAPK14SMN1; SMN2LMNAMMP13CYP3A4 | |
| SCHEMBL14966579 | 0.87 | LMNA (0.56) | SMN1; SMN2LMNAHTTALDH1A1KLKB1 | |
| SCHEMBL14966854 | 0.87 | LMNA (0.61) | MAPK14SMN1; SMN2LMNAALDH1A1KLKB1 | |
| SCHEMBL14966509 | 0.86 | KLKB1 (0.50) | MAPK14HPGDCYP3A4GRM5ALDH1A1 | |
| SCHEMBL14966950 | 0.86 | MAPK14 (0.55) | MAPK14HPGDSMN1; SMN2LMNAMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206128-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206128-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140288123-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| EP-2780014-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013075083-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013075083-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288123-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | MAPK14 4092/4885HPGD 1295/4885SMN1; SMN2 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.